{"title":"[A case of intractable pneumothorax in a patient with pulmonary adenocarcinoma during bevacizumab-containing chemotherapy].","authors":"Takashi Tamura, Shinobu Tamura, Hideki Nasu, Tokuzo Fujimoto, Takahiro Kinoshita","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The patient was a 70-year-old woman. She was admitted to our hospital complaining of fever and dyspnea. Chest CT scan showed a 50 x 30-mm tumorous shadow in S6 of the left lung and honeycomb lung in both lower lobes. As the result of cytodiagnosis with ultrasonic echo, adenocarcinoma was diagnosed. Clinical stage was IIIA (T3N2M0). We selected carboplatin and paclitaxel with bevacizumab as first-line chemotherapy, but at 7 days after the initiating it, the chest X-ray showed left pneumothorax. A chest drainage tube was placed in the left thoracic cavity. The patient was treated repeatedly pleurodesis with minocycline and OK-432. The pneumothorax required 3 weeks to cure. We selected carboplatin and paclitaxel without bevacizumab for the second course, and the pneumothorax did not recur. Pneumothorax was a serious adverse event associated with bevacizumab-containing chemotherapy. It is necessary to be aware of the possibility of pneumothorax when we treat lung adenocarcinoma with bevacizumab-containing chemotherapy.</p>","PeriodicalId":19218,"journal":{"name":"Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society","volume":"49 9","pages":"702-6"},"PeriodicalIF":0.0000,"publicationDate":"2011-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The patient was a 70-year-old woman. She was admitted to our hospital complaining of fever and dyspnea. Chest CT scan showed a 50 x 30-mm tumorous shadow in S6 of the left lung and honeycomb lung in both lower lobes. As the result of cytodiagnosis with ultrasonic echo, adenocarcinoma was diagnosed. Clinical stage was IIIA (T3N2M0). We selected carboplatin and paclitaxel with bevacizumab as first-line chemotherapy, but at 7 days after the initiating it, the chest X-ray showed left pneumothorax. A chest drainage tube was placed in the left thoracic cavity. The patient was treated repeatedly pleurodesis with minocycline and OK-432. The pneumothorax required 3 weeks to cure. We selected carboplatin and paclitaxel without bevacizumab for the second course, and the pneumothorax did not recur. Pneumothorax was a serious adverse event associated with bevacizumab-containing chemotherapy. It is necessary to be aware of the possibility of pneumothorax when we treat lung adenocarcinoma with bevacizumab-containing chemotherapy.
患者是一名70岁的妇女。她因发烧和呼吸困难住进我院。胸部CT示左肺S6区50 x 30 mm肿瘤影,双肺下叶蜂窝状肺。超声超声细胞诊断诊断为腺癌。临床分期为IIIA (T3N2M0)。我们选择卡铂、紫杉醇联合贝伐单抗作为一线化疗方案,但在开始化疗后7天,胸部x线显示左侧气胸。左胸腔内置入胸腔引流管。患者接受二甲胺四环素和OK-432反复胸膜融合术治疗。气胸需要3周才能治愈。我们选择卡铂和紫杉醇不加贝伐单抗治疗第二个疗程,气胸没有复发。气胸是与含贝伐单抗化疗相关的严重不良事件。当我们使用含贝伐单抗的化疗治疗肺腺癌时,有必要意识到气胸的可能性。